Meeting an un-MET need: Targeting MET in non-small cell lung cancer

The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). MET exon 14 skipping mutations occur in 3-4% of patients with NSCLC, while MET amplifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaels, Elena, Bestvina, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634070/
https://www.ncbi.nlm.nih.gov/pubmed/36338701
http://dx.doi.org/10.3389/fonc.2022.1004198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634070/
https://www.ncbi.nlm.nih.gov/pubmed/36338701
http://dx.doi.org/10.3389/fonc.2022.1004198

Ejemplares similares